# CSL Behring signs nine-year plasma supply agreement with National Blood Authority

CSL Behring signed a new National Fractionation Agreement with the National Blood Authority of Australia to supply plasma-derived therapies manufactured at its Broadmeadows facility. The agreement runs from 1 January 2018 to 31 December 2026.

- Type: Contract
- Announced: 2017-12-11
- Where: Broadmeadows, Victoria, Australia
- Status: announced
- Products: plasma-derived therapies

## Companies

- [CSL Behring](https://endata.com/companies/28726.md)
- [National Blood Authority](https://endata.com/companies/28727.md) (customer)

## Sources

- [newsroom.csl.com](https://newsroom.csl.com/2017-12-11-CSL-Behring-Australia-and-National-Blood-Authority-Sign-New-National-Fractionation-Agreement-for-Australia), 2017-12-11: "CSL Behring welcomes the opportunity to continue our longstanding commitment to provide plasma-derived therapies to treat people in Australia with serious medical conditions."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.